TARRYTOWN, N.Y., Oct. 24, 2012 -- TARRYTOWN, N.Y., Oct. 24, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial and operating results for the third quarter of 2012 and provided an update on development programs. The Company reported total revenues of $428 million in the third quarter and $964 million in the first nine months of 2012. Total revenues included EYLEA net product sales of $244 million in the third quarter and $562 million in the first nine months of 2012.
